A detailed history of Versant Capital Management, Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Versant Capital Management, Inc holds 10 shares of BPMC stock, worth $916. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10
Previous 10 -0.0%
Holding current value
$916
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 10, 2023

BUY
$42.2 - $66.37 $422 - $663
10 New
10 $0
Q1 2022

Apr 29, 2022

BUY
$54.1 - $110.08 $270 - $550
5 New
5 $0
Q4 2019

Jan 28, 2020

SELL
$66.73 - $82.59 $3,002 - $3,716
-45 Closed
0 $0
Q3 2019

Oct 18, 2019

BUY
$72.9 - $101.41 $3,280 - $4,563
45 New
45 $3,000
Q2 2019

Jul 16, 2019

SELL
$73.54 - $97.8 $514 - $684
-7 Closed
0 $0
Q1 2019

Apr 23, 2019

BUY
$48.7 - $86.6 $340 - $606
7 New
7 $0
Q1 2019

Apr 23, 2019

BUY
$48.7 - $86.6 $0 - $0
0 New
0 $0

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.47B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.